November 15, 2019 — Theragnostics, which is developing innovative radiopharmaceuticals to improve cancer diagnosis and treatment, announced the successful completion of a phase two clinical study of novel prostate cancer diagnostic imaging Gallium-68 (68Ga) THP-PSMA PET/CT.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now